COR · NYQ · Healthcare
Cencora, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 319.40
Market price
USD 308.78
Implied upside
+3.4%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 354.9bn | USD 391.9bn | USD 432.8bn | USD 477.9bn | USD 527.8bn | +10.4% |
| EBIT | USD 4.0bn | USD 4.4bn | USD 4.8bn | USD 5.3bn | USD 5.9bn | +10.4% |
| NOPAT | USD 3.1bn | USD 3.5bn | USD 3.8bn | USD 4.2bn | USD 4.7bn | +10.4% |
| Add depreciation & amortisation | USD 1.2bn | USD 1.4bn | USD 1.5bn | USD 1.7bn | USD 1.8bn | +10.4% |
| Less capital expenditure | USD -3.5bn | USD -3.9bn | USD -4.3bn | USD -4.8bn | USD -5.3bn | +10.4% |
| Less increase in working capital | USD 315.1m | USD 347.9m | USD 384.2m | USD 424.3m | USD 468.6m | -10.4% |
| Free cashflow to firm | USD 1.1bn | USD 1.3bn | USD 1.4bn | USD 1.5bn | USD 1.7bn | +10.4% |
| Discount factor | 0.9599 | 0.8844 | 0.8149 | 0.7508 | 0.6917 | - |
| Present value | USD 1.1bn | USD 1.1bn | USD 1.1bn | USD 1.1bn | USD 1.2bn | +1.8% |
| Present Value Of The Forecast | USD 5.6bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.715 | Reported 0.574, pulled toward 1.0 (Blume) |
| Cost of equity | 8.93% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.97% | Interest expense / average total debt |
| Market capitalisation | USD 58.9bn | 88.5% of capital |
| Total debt | USD 7.7bn | 11.5% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.53% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
91% of EV
- Forecast FCFF, final year
- USD 1.7bn
- Capex at depreciation, working capital in reinvestment
- USD 5.5bn
- Less reinvestment at g/ROIC (6.3% of NOPAT)
- USD -342.5m
- Capitalised
- USD 5.1bn
- ROIC (reported)
- 39.8%
- Terminal value, undiscounted
- USD 86.8bn
- Terminal value, discounted
- USD 60.0bn
- Enterprise value
- USD 65.7bn
- Less net debt
- USD 3.3bn
- Equity value
- USD 62.4bn
Exit at 12.4x EBITDA
92% of EV
- Terminal value, undiscounted
- USD 96.2bn
- Terminal value, discounted
- USD 66.6bn
- Enterprise value
- USD 72.2bn
- Less net debt
- USD 3.3bn
- Equity value
- USD 68.9bn
Spread between methods: 10%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.53% | 420.78 | 462.01 | 513.39 | 579.22 | 666.68 |
| 7.53% | 338.55 | 365.08 | 396.84 | 435.54 | 483.77 |
| 8.53% | 280.11 | 298.27 | 319.39 | 344.29 | 374.09 |
| 9.53% | 236.57 | 249.56 | 264.36 | 281.38 | 301.19 |
| 10.53% | 202.97 | 212.57 | 223.34 | 235.50 | 249.37 |
Outlined: this model. Green text: above today's price of 308.78. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 10.4% | 9.7% | -0.7pp |
| EBIT margin | 1.1% | 1.1% | -0.0pp |
| Discount rate | 8.5% | 8.7% | +0.2pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.